Proteomics

Dataset Information

83

Proteomic signature of neuroblastoma cells UKF-NB-4 reveals key role of lysosomal sequestration and the proteasome complex in acquiring chemoresistance to cisplatin


ABSTRACT: Cisplatin (CDDP) is a widely used agent in the treatment of neuroblastoma. Unfortunately, the development of acquired chemoresistance limits its clinical use. To gain a detailed understanding of the mechanisms underlying the development of such chemoresistance, we comparatively analysed established cisplatin-resistant neuroblastoma cell line (UKF-NB- 4CDDP) and its sensitive counterpart (UKF-NB-4). We confirmed the decreased sensitivity of tested cells to cisplatin and identified a cross-resistance to carboplatin and oxaliplatin. Among the proteins responsible for UKF-NB-4CDDP chemoresistance, ion channels transport family proteins, ABC superfamily proteins, SLC-mediated trans-membrane transporters, proteasome complex subunits and V-ATPases were identified. Moreover, we detected markedly higher proteasome activity in UKF-NB-4CDDP cells and a remarkable lysosomal enrichment that can be inhibited by bafilomycin A to sensitize UKF-NB-4CDDP to CDDP. Our results indicate that lysosomal sequestration and proteasome activity may be one of key mechanisms responsible for intrinsic chemoresistance of neuroblastoma to CDDP.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo sapiens  

TISSUE(S): Cell Culture

DISEASE(S): Neuroblastoma

SUBMITTER: Vivian de los Rios  

LAB HEAD: Vivian de los Rios

PROVIDER: PXD012132 | Pride | 2019-01-02

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
MUESTRA1.msf Msf
MUESTRA1.raw Raw
MUESTRA2.msf Msf
MUESTRA2.raw Raw
MUESTRA3.msf Msf
Items per page:
1 - 5 of 18
altmetric image

Publications

Proteomic Signature of Neuroblastoma Cells UKF-NB-4 Reveals Key Role of Lysosomal Sequestration and the Proteasome Complex in Acquiring Chemoresistance to Cisplatin.

Merlos Rodrigo Miguel Angel MA   Buchtelova Hana H   de Los Rios Vivian V   Casal José Ignacio JI   Eckschlager Tomas T   Hrabeta Jan J   Belhajova Marie M   Heger Zbynek Z   Adam Vojtech V  

Journal of proteome research 20190111 3


Cisplatin (CDDP) is a widely used agent in the treatment of neuroblastoma. Unfortunately, the development of acquired chemoresistance limits its clinical use. To gain a detailed understanding of the mechanisms underlying the development of such chemoresistance, we comparatively analyzed established cisplatin-resistant neuroblastoma cell line (UKF-NB-4<sup>CDDP</sup>) and its sensitive counterpart (UKF-NB-4). First, using viability screenings, we confirmed the decreased sensitivity of tested cell  ...[more]

Similar Datasets

2021-01-01 | S-EPMC7943580 | BioStudies
2019-01-01 | S-EPMC6469049 | BioStudies
2020-01-01 | S-EPMC7555145 | BioStudies
2014-01-01 | S-EPMC4154694 | BioStudies
2017-01-01 | S-EPMC5520548 | BioStudies
2017-01-01 | S-EPMC5305101 | BioStudies
2013-01-01 | S-EPMC3817081 | BioStudies
2016-01-01 | S-EPMC4723083 | BioStudies
2017-01-01 | S-EPMC5410270 | BioStudies
2016-01-01 | S-EPMC5109645 | BioStudies